Multiple myeloma (supportive care)
Also known as: Multiple myeloma, Plasma cell myeloma, Symptomatic myeloma
Multiple myeloma is a plasma cell neoplasm characterised by osteolytic lesions, anaemia, renal insufficiency, and heightened susceptibility to infection. Supportive care must remain coordinated with haematology and prescribed anticancer treatment. Chinese-medicine assessment may provide a traditional framework for discussing fatigue, appetite, sleep, and discomfort, but must not reinterpret progressive disease as pattern imbalance. The supplied records provide no evidence for acupuncture or herbal treatment in myeloma: one concerns adolescent mental health, one explores cancer-related financial barriers [2], and one lacks an abstract. Safety protocols reflect general clinical precautions rather than findings established by these records. Any complementary therapeutic involvement requires individual oncological review.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Prioritise all haematological consultations and prescribed regimens; engage social work services if logistical or financial barriers compromise treatment adherence.
- •Adhere to a tailored physical activity plan focused on bone preservation; avoid high-impact movements, heavy lifting, or forceful spinal manipulation unless specifically cleared by a specialist.
- •Maintain strict compliance with dietary and fluid intake protocols and oral hygiene routines, particularly in the context of renal impairment or treatment-induced stomatitis.
- •Systematically document symptoms, including pain intensity, fatigue levels, and body temperature; strictly observe oncology protocols regarding infection prophylaxis and immunisation.
Cautions & Contraindications
- •Defer needling with active infection, fever or clinically significant neutropenia pending oncology clearance. Use current blood counts and local oncology protocols rather than a universal threshold. Record [2] does not evaluate needling safety.[]
- •Avoid needling with active bleeding or clinically significant thrombocytopenia; anticoagulant use requires individual bleeding-risk assessment. Record [2] does not establish haematological safety thresholds.[]
- •Do not needle through infected, ulcerated or fragile irradiated skin, near vascular access devices, or over known tumour deposits or unstable skeletal lesions. Record [2] does not address anatomical contraindications.[]
- •Do not initiate herbal products without oncology/pharmacist reconciliation of anticancer medicines, thromboprophylaxis, renal function and product quality; transplantation requires specific team approval. Record [2] does not establish herb–medicine compatibility.[]
- •Avoid vigorous massage, manipulation or strong local stimulation over myeloma-affected bone. Pregnancy requires modified acupuncture planning and specialist review before any herbal prescription. Record [2] does not evaluate these precautions.[]
When to reassess or seek care again
Record baseline pain and fatigue on 0–10 scales, sleep disruption, appetite, functional activity and adverse effects. If oncology clears a short supportive trial, review after 1–2 weeks or 2–3 visits. Stop if there is no meaningful patient-reported benefit or any adverse effect. New or worsening focal pain, declining function, reduced intake or infection symptoms require medical review without waiting for the scheduled reassessment. Recheck suitability whenever treatment phase or blood counts change.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Global mental health (Cambridge, England) · 2025
- Frontiers in psychology · 2023
- Journal of managed care pharmacy : JMCP · 2012
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
